BridgeMD
Compares treatment options for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Official title A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov ID: NCT07680764
What this study is testing
What is Pumitamig?
Pumitamig is an investigational medicine, being studied as a potential treatment for locally advanced non-small cell lung cancer (nsclc).
Also referred to as BMS-986545, BNT327.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent...
- Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
- Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the...
- Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
- Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
You likely can't join if
- Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated.
- Participants must not have prior treatment with immuno-oncology therapies.
- Participants must not have untreated central nervous system (CNS) metastases.
- Other protocol-defined Inclusion/Exclusion criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- Athens, Georgia, United States
- Lexington, Kentucky, United States
- Baltimore, Maryland, United States
- Hattiesburg, Mississippi, United States
- Grand Island, Nebraska, United States
- Omaha, Nebraska, United States
- New York, New York, United States
- Nashville, Tennessee, United States
- Houston, Texas, United States
- Madison, Wisconsin, United States
- Viedma, Río Negro Province, Argentina
- Rosario, Santa Fe Province, Argentina
- Buenos Aires, Argentina
- Gosford, New South Wales, Australia
- Westmead, New South Wales, Australia
- Greenslopes, Queensland, Australia
- Heidelberg, Victoria, Australia
- Perth, Western Australia, Australia
- Natal/RN, Rio Grande do Norte, Brazil
- Porto Alegre, Rio Grande do Sul, Brazil
+ 45 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Athens, Georgia, United States; Lexington, Kentucky, United States; Baltimore, Maryland, United States; Hattiesburg, Mississippi, United States; Grand Island, Nebraska, United States; Omaha, Nebraska, United States and 59 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.